Immunotherapy for Type 1 Diabetes
The Immunotherapy for Type 1 diabetes session at Diabetics 2026 emphasizes recent developments in immune-based treatments and research efforts aimed at improving long-term outcomes for individuals with type 1 diabetes. Type 1 diabetes results from an autoimmune response that damages insulin-producing beta cells in the pancreas. Immunotherapy offers promising possibilities to modify immune activity, preserve remaining beta cells, and delay disease progression.
Sub-Tracks:
- Autoimmune Mechanisms
- Immune Modulation
- T-Cell Responses
- Beta Cell Protection
- Antigen-Specific Therapy